West China Hospital Neurosurgery: Skull-Base, Glioma and Vascular Teams

A department built in stages, not a single clinic

West China Hospital's neurosurgery department developed from a group founded in 1956 and became independent in 1984. The official overview records national clinical-key-specialty status and World Federation of Neurosurgical Societies continuing-education activity. Its directory separates skull-base, cerebrovascular, glioma and deep-tumor work from functional surgery, spine and spinal cord, pediatric cases, monitoring and navigation, trauma and peripheral nerves.

That separation is the useful starting point. A pituitary adenoma, a function-sensitive glioma and a ruptured aneurysm do not pass through the same clinical pathway simply because all three sit under neurosurgery. The department's own programme pages describe different teams, techniques and research histories for each. Reading them together gives a more accurate picture than a hospital-wide reputation line, and it tells a patient which records and questions belong in the first conversation.

Skull base and pituitary: a programme dating from 2005

The hospital's anterior and middle skull-base programme was established in 2005. Its page describes work on meningioma, craniopharyngioma, pituitary adenoma, cranio-orbital and sinonasal lesions, and schwannoma, with endoscopy, navigation and monitoring used alongside multidisciplinary input. This is a description of a clinical direction, not a statement that every lesion in that list is treated the same way or that any particular patient is a candidate for an endoscopic route.

The pituitary multidisciplinary center was established in November 2012, with Jiang Shu and Cai Bowen named alongside endocrine, pathology and imaging partners. An enquiry can ask which part of a pituitary assessment the patient wants reviewed and whether several specialties would examine the available findings together. That keeps the discussion focused on the unresolved clinical decision rather than choosing an operative approach in advance.

Xu Jianguo and You Chao are also identified as leaders of a craniopharyngioma research group studying tumor biology, animal models and treatment strategies since 1995. That is a documented research-group role. For a family seeking another opinion, specify the diagnosis used by the current team and the particular concern it wants reviewed, then ask which existing information the receiving program requires.

Craniopharyngioma: framing the question for a multidisciplinary review

Craniopharyngioma is a named focus of the anterior and middle skull-base program rather than a generic brain-tumor label. The program's research spans biology, animal models and treatment strategies. For a family reading about that work, it is useful to separate questions about the diagnosis from questions about a previous treatment decision or future assessment. Explain what has already been discussed with the current clinicians and where another opinion would be helpful.

The pituitary center's documented multidisciplinary structure also gives families a specific question to ask: which specialists would contribute to the assessment, and how would their findings be brought together? A named research group and an established center do not themselves answer an individual treatment question. The receiving team should explain what it can assess from the existing information and what would still need an examination or further clarification.

Glioma and deep tumours: imaging, navigation and awake techniques

The glioma and deep brain tumour programme was also established in 2005. Its page names Mao Qing, Liu Yanhui and Wang Xiang as representative clinicians, and describes a focus that combines deep-seated lesions with function-sensitive glioma surgery, using multimodal imaging, navigation, fluorescence and awake-surgery techniques. These methods describe the program's scope; an individual approach requires assessment.

A multidisciplinary tumour board has been documented since 2012, involving imaging, pathology, oncology, neurology and rehabilitation. The programme also refers to a Sichuan glioma clinical and bioinformatics resource and to research publications, with provincial or ministry science-progress second recognition recorded without a named year or project on the page. For an overseas patient, the practical value of that structure is the sequence of questions it implies: how imaging and pathology would be reviewed together, whether molecular testing would change the discussion, what rehabilitation input is available, and what the team would need from the patient's own hospital. Suitability and the actual plan remain clinical judgements.

Cerebrovascular work and a 2023 research landmark

The cerebrovascular programme page traces the department's development of microsurgical clipping, endovascular treatment and hybrid approaches for aneurysms and brain or spinal vascular lesions. You Chao, Mao Boyong, Xie Xiaodong and He Min appear as contributors.

One dated item stands out. In May 2023, research by You Chao's team on brain haemorrhage was published in The Lancet and selected among China's important medical advances for that year. That is recognition of research work. It is not evidence that a particular intervention is right for a particular patient, and it says nothing about how any individual would fare.

This is also where an overseas reader needs the clearest boundary. A suspected stroke, a sudden severe headache or a deteriorating conscious level is an emergency to be assessed locally and immediately. Nothing in a hospital's research record justifies delaying urgent care while considering travel to China. For stable, already-investigated vascular lesions, the questions are different: what imaging exists, what treatments have already been discussed, and what the treating team would need to form its own view.

Functional work, peripheral nerves and the 2025 subgroup

The functional neurosurgery page describes a historical development that includes epilepsy surgery, microvascular decompression for trigeminal neuralgia and hemifacial spasm, stereotactic radiosurgery and deep brain stimulation-related neuromodulation. Lei Ting and Wang Wei are named as historical programme contributors, and the page also lists Chen Jing, Fang Fang and Li Peng as representatives. The body includes data ending in 2018 alongside undated later paragraphs, so it should be read as a record of how the programme developed rather than a description of current 2026 activity, device availability or results.

The peripheral nerve subgroup is newer: the department page dates it to 2025, and its own page identifies Tian Rui and Zhang Fan as representative physicians. Documented directions include nerve tumours, entrapment, injury, reconstruction and selected neuropathic pain, with mention of multicentre prospective research. An enquiry can distinguish a diagnosed peripheral-nerve lesion from an unresolved symptom and ask which program could assess the existing findings.

Research honors and preparing a specialist enquiry

The skull-base program records a 2008 Chinese Medical Science and Technology First Prize, a 2016 education science-progress Second Prize, a 2016 Huaxia medical Third Prize and a 2023 Sichuan science-progress First Prize for the craniopharyngioma group. It separately attributes a 2023 Sichuan science-progress Second Prize to Zhou Liangxue's team. These are distinct research recognitions, not interchangeable awards for everyone in the department.

The department placed third in the Fudan 2023 national specialty reputation list. This is a historical departmental reference, not a ranking of the skull-base, vascular, glioma or functional programs, and it does not identify the clinician most suitable for a particular patient. The program descriptions provide the more specific starting point: they connect a disease area with documented clinical contributors and research activity.

A concise enquiry can state the diagnosis already recorded, earlier treatment and the decision on which another opinion is sought. Ask which existing scans, reports or operative records should be supplied and whether the proposed response is a records-based opinion or an in-person assessment. Confirm the hospital's acceptance and arrangements before making travel plans.

ChinaSpecialistCare can help match a neurosurgical enquiry to the relevant clinical direction, organise records and coordinate a visit after hospital acceptance. We are independent of the hospital and cannot promise a named clinician, acceptance or outcome. An initial enquiry is free; purchasing a proxy consultation is not required.

Neurosurgery care in China